Holen Sie sich die Stockscreener-App
5.162
0.86%
-0.048
Schlusskurs vom Vortag:
$5.21
Offen:
$5.16
24-Stunden-Volumen:
861.80K
Relative Volume:
1.03
Marktkapitalisierung:
$1.16B
Einnahmen:
$596.48M
Nettoeinkommen (Verlust:
$123.72M
KGV:
9.4128
EPS:
0.5484
Netto-Cashflow:
$106.59M
1W Leistung:
+1.08%
1M Leistung:
-0.86%
6M Leistung:
+15.29%
1J Leistung:
+53.26%
1-Tages-Spanne:
$5.105
$5.21
1-Wochen-Bereich:
$5.1045
$5.31
52-Wochen-Spanne:
$2.475
$5.72
Curevac N V Stock (CVAC) Company Profile
Vergleichen Sie CVAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.16 | 1.17B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-25 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-01-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-01-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-06-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2020-12-10 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-09-08 | Eingeleitet | Credit Suisse | Neutral |
| 2020-09-08 | Eingeleitet | Jefferies | Hold |
Alle ansehen
Curevac N V Aktie (CVAC) Neueste Nachrichten
Trading Recap: Chien thuat ca cuoc dai han de kiem tienQuarterly Earnings Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
Can CureVac N.V. stock reach $100 price targetWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
CureVac N.V. (CVAC): A Bull Case Theory - Finviz
Can CureVac N.V. stock sustain market leadershipGlobal Markets & Proven Capital Preservation Tips - Newser
BioNTech Satisfies Minimum Condition in CureVac Exchange Offer - TipRanks
BioNTech satisfies minimum condition in CureVac exchange offer - MSN
Biontech achieves minimum condition in CureVac exchange offer - marketscreener.com
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - The Manila Times
BioNTech Announces Successful Tender of Over 81% of CureVac Shares, Subsequent Offering Period Now Open - Quiver Quantitative
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - Benzinga
Movement Recap: Can MFSG stock resist broad market declinesQuarterly Performance Summary & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline? - simplywall.st
CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators - Markets Mojo
How CureVac N.V. stock reacts to Fed rate cutsEarnings Risk Report & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC - MarketBeat
Transcript : CureVac N.V.Shareholder/Analyst Call - MarketScreener
CureVac (NASDAQ:CVAC) Sees Large Volume IncreaseHere's What Happened - MarketBeat
BioNTech Advances with CureVac Exchange Offer Approval - TipRanks
[6-K] BioNTech SE Current Report (Foreign Issuer) | BNTX SEC FilingForm 6-K - Stock Titan
CureVac Reports Q3 2025 Financial Results and Updates - MSN
CureVac Shareholders Approve BioNTech Exchange Offer - TipRanks
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com Nigeria
CureVac Form 6-K files EGM voting outcomes, joins BioNTech F-4 - Stock Titan
BioNTech (BNTX) Moves Forward with CureVac Acquisition - GuruFocus
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3 - Seeking Alpha
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - The Manila Times
BioNTech Completes CureVac Share Exchange Offer Following Shareholder Approval - Quiver Quantitative
BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025 - TradingView
BioNTech exchange offer for CureVac expires December 3 - StreetInsider
CureVac NV earnings beat by €0.08, revenue topped estimates - Investing.com South Africa
CureVac NV (FRA:5CV) PS Ratio : 14.01 (As of Nov. 25, 2025) - GuruFocus
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting - sharewise.com
CureVac (Nasdaq: CVAC) shareholders approve BioNTech exchange offer with 99.16% vote - Stock Titan
CureVac Announces Voting Results of Extraordinary General Meeting - The Derrick
How Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly Sales - Yahoo Finance
CureVac Beats Revenue Forecasts As BioNTech Takeover Advances - Finimize
CureVac (NASDAQ:CVAC) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
CureVac: Acquisition proceeding as planned; cash runway confirmed through 2028 - marketscreener.com
Company News for Nov 25, 2025 - sharewise.com
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
MSN Money - MSN
CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress - TipRanks
CVAC: Q3 2025 profit driven by one-time U.S. settlement, despite sharp revenue drop - TradingView
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - sharewise.com
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher - Benzinga
[6-K] CureVac N.V. Current Report (Foreign Issuer) | CVAC SEC FilingForm 6-K - Stock Titan
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position - GuruFocus
CureVac (CVAC) Reports Decrease in Q3 EPS - GuruFocus
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations - GuruFocus
CureVac (CVAC) Reports Strong Cash Position as Strategic Measures Pay Off - GuruFocus
Finanzdaten der Curevac N V-Aktie (CVAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):